Cargando...
Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease with poor prognosis. Although reports suggest that integrin-linked kinase (ILK) is a potential target for ovarian c...
Guardado en:
| Publicado en: | Cancers (Basel) |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7226328/ https://ncbi.nlm.nih.gov/pubmed/32260415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040880 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|